期刊
CLINICAL IMMUNOLOGY
卷 142, 期 2, 页码 107-116出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2011.09.011
关键词
Galectin-1; Galectin-1 ligands; Immunoregulation; Cancer immune evasion; Carbohydrate therapeutics; Immunotherapy
类别
资金
- NIH/NCI [CA118124]
- NIH/NCCAM [AT004268]
Galectin-1 (Gal-1) is one of 15 evolutionarily conserved B-galactoside-binding proteins that display biologically-diverse activities in pathogenesis of inflammation and cancer. Gal-1 is variably expressed on immune cells and endothelial cells, though is commonly found and secreted at high levels in cancer cells. It induces apoptosis in effector T cells through homodimeric binding of N-acetyllactosamines on membrane glycoproteins (Gal-1 ligands). There is also compelling evidence in models of cancer and autoimmunity that recombinant Gal-1 (rGal-1) can potentiate immunoregulatory function of T cells. Here, we review Gal-1's structural and functional features, while analyzing potential drawbacks and technical difficulties inherent to rGal-1's nature. We also describe new Gal-1 preparations that exhibit dimeric stability and functional activity on T cells, providing renewed excitement for studying Gal-1 efficacy and/or use as anti-inflammatory therapeutics. We lastly summarize strategies targeting the Gal-1 Gal-1 ligand axis to circumvent Gal-1-driven immune escape in cancer and boost anti-tumor immunity. (C) 2011 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据